Breakthrough trial aims to slash treatment time for Tough-to-Treat TB

NCT ID NCT06649721

Summary

This Phase 3 trial is testing a new, shorter treatment for a dangerous form of tuberculosis (TB) that resists standard drugs. It aims to see if a 6-month, all-pill regimen is effective and safe for Chinese teenagers and adults with rifampin-resistant pulmonary TB. Researchers will follow 120 participants to check if the treatment clears the infection and monitor for serious side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Anhui Chest Hospital

    Hefei, Anhui, China

  • Beijing Chest Hospital

    Beijing, China

  • Changsha Central Hospital

    Changsha, Hunan, China

  • Harbin Chest Hospital

    Harbin, Helongjiang, China

  • Hebei Chest Hospital

    Shijiazhuang, Hebei, China

  • Henan Chest Hospital

    Zhengzhou, Henan, China

  • Henan Infectious Disease Hospital

    Zhengzhou, Henan, China

  • Huashan Hospital

    Shanghai, China

  • Hulunbuir Infectious Disease Hospital

    Hulunbuir, Inner Mongolia, China

  • Infectious Disease Hospital of Changchun

    Changchun, Jilin, China

  • Infectious Disease Hospital of Heilongjiang Province

    Harbin, Heilongjiang, China

  • Jiamusi Tuberculosis Hospital(Jiamusi Cancer Hospital)

    Jiamusi, Heilongjiang, China

  • Jiangxi Chest Hospital

    Nanchang, Jiangxi, China

  • Jilin Tuberculosis Hospital

    Jilin, Jilin, China

  • Linyi People Hospital

    Linyi, Shandong, China

  • Liupanshui Third People's Hospital

    Liupanshui, Guizhou, China

  • Luoyang Center Hospital

    Luoyang, Henan, China

  • Public Health Clinical Center of Chengdu

    Chengdu, Sichuan, China

  • Qingdao Chest Hospital

    Qingdao, Shandong, China

  • Shandong Public Health Clinical Center, Shandong University

    Jinan, Shandong, China

  • Shanxi Medical University Affiliated Chest Hospital

    Taiyuan, Shanxi, China

  • Shenyang Chest Hospital

    Shenyang, Liaoning, China

  • The 8th Medical Center of Chinese PLA General Hospital

    Beijing, Beijing Municipality, China

  • The Fifth Hospital of Shijiazhuang

    Shijiazhuang, Hebei, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, China

  • The Fourth People's Hospital of Nanning

    Nanning, Guangxi, China

  • The Second Hospital of Nanjing

    Nanjing, Jiangsu, China

  • Tianjin Haihe Hospital

    Tianjin, Tianjin Municipality, China

  • Weifang No.2 People's Hospital

    Weifang, Shandong, China

  • Wenzhou Central Hospital

    Wenzhou, Zhejiang, China

  • Wuhan Pulmonary Hospital,Wuhan Tuberculosis Prevention and Control Institute

    Wuhan, Hubei, China

  • Xi'an Chest Hospital

    Xi'an, Shaanxi, China

  • Yantai Qishan Hospital

    Yantai, Shandong, China

Conditions

Explore the condition pages connected to this study.